Published online Apr 26, 2022. doi: 10.12998/wjcc.v10.i12.3866
Peer-review started: August 16, 2021
First decision: October 22, 2021
Revised: November 4, 2021
Accepted: March 6, 2022
Article in press: March 6, 2022
Published online: April 26, 2022
Processing time: 247 Days and 21.9 Hours
The outbreak of the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 has been the most important clinical challenge worldwide since January 2020. COVID-19 inactivated vaccines play a crucial role in reducing the rates of morbidity and mortality.
We presented a 48-year-old woman from Haidian District, Beijing, China who developed ischemic colitis after receiving the second dose of COVID-19 inactivated vaccine. Computed tomography of the abdomen showed edema and bowel wall thickening with hypodensity in the sigmoid colon and descending colon. Colonoscopy revealed hyperemia, edema and erosion of the mucosa with superficial ulceration and a yellow-white coating at the descending colon and sigmoid colon. The symptoms were relieved after 1 wk of receiving pinaverium bromide (50 mg, tid) and aspirin enteric-coated tablets (0.1 g, qd).
The possible occurrence of ischemic colitis should be considered after administration of the COVID-19 inactivated vaccines.
Core Tip: Coronavirus disease 2019 (COVID-19) inactivated vaccines play a crucial role in reducing the rates of morbidity and mortality. The adverse events after administration of inactivated vaccines are varied and need to be profoundly studied in clinical practice. This report described the relationship between the administration of the COVID-19 inactivated vaccine with ischemic colitis and its possible causes. The potential mechanism behind the development of ischemic colitis needs further exploration to better understand and manage unforeseen complications of COVID-19 inactivated vaccines.